MNKD
MannKind Corporation
MNKD
MannKind Corporation
Three revenue streams continue to feed modest growth for MannKind. Two new FDA approvals show promise of turbocharging product growth in two of MNKD's established products. MNKD's existing liquidity s
Mannkind Corporation (NASDAQ:MNKD) shares are trading higher as the company recently announced the U.S. Food and Drug Administration's (FDA) approval of Furoscix ReadyFlow, an at-home treatment option
MannKind NASDAQ: MNKD said the U.S. Food and Drug Administration approved Furoscix ReadyFlow, an auto-injector designed to deliver an 80-milligram dose of subcutaneous furosemide in five to 10 seconds